Glutamine Supplementation and Short-term Mortality in Covid-19
- Conditions
- Covid19
- Registration Number
- NCT04909905
- Lead Sponsor
- Assiut University
- Brief Summary
The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19 diseased patients.
- Detailed Description
A written informed consent will be taken from the patients or their relatives. Patients with diagnosis of covid-19 with enteral nutrition will be enrolled. Patients will be randomly assigned to receive either standard enteral nutrition (Group EN) or intravenous glutamine supplementation to enteral nutrition (group GN) in a dose of glutamine of 0.4 g/kg/day during ICU stay.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Diagnosis of covid-19 diseased patients admitted to the ICU with enteral nutrition.
- Renal failure (creatinine >180 mmol/l)
- Hepatic failure (bilirubin >40 mmol/l, alanine aminotransferase >100 U/l and aspartate aminotransferase >100 U/l)
- Severe neutropenia (<500 cells/mm3)
- Patients receiving cytotoxic, radiation and/or steroid therapy
- Hemodynamic instability
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method ICU mortality 7 days Short-term ICU mortality for patients admitted in our ICU \& signed for study drugs, who will expire during the study
- Secondary Outcome Measures
Name Time Method Neutrophil/lymphocyte ratio (NLR) 7 days Assessing NLR at day zero \& day 7 to monitor inflammatory response
D- dimer level 7 days Assessing D-dimer level at day zero \&day 7 to monitor coagulability status
ICU stay 7 days Period of patients admission in ICU within duration of study
Trial Locations
- Locations (1)
Omar Soliman
🇪🇬Assiut, Assuit, Egypt
Omar Soliman🇪🇬Assiut, Assuit, Egypt